Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
Identifieur interne : 000191 ( Main/Exploration ); précédent : 000190; suivant : 000192Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
Auteurs : Marta Boffito [Royaume-Uni] ; David J. Back [Royaume-Uni] ; Charles Flexner [États-Unis] ; Peter Sjö [Suisse] ; Terrence F. Blaschke [États-Unis] ; Peter W. Horby [Royaume-Uni] ; Dario Cattaneo [Italie] ; Edward P. Acosta [États-Unis] ; Peter Anderson [États-Unis] ; Andrew Owen [Royaume-Uni]Source :
- Clinical pharmacology and therapeutics [ 1532-6535 ] ; 2020.
Abstract
The urgent global public health need presented by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has brought scientists from diverse backgrounds together in an unprecedented international effort to rapidly identify interventions. There is a pressing need to apply clinical pharmacology principles and this has already been recognized by several other groups. However, one area that warrants additional specific consideration relates to plasma and tissue protein binding that broadly influences pharmacokinetics and pharmacodynamics. The principles of free drug theory have been forged and applied across drug development but are not currently being routinely applied for SARS-CoV-2 antiviral drugs. Consideration of protein binding is of critical importance to candidate selection but requires correct interpretation, in a drug-specific manner, to avoid either underinterpretation or overinterpretation of its consequences. This paper represents a consensus from international researchers seeking to apply historical knowledge, which has underpinned highly successful antiviral drug development for other viruses, such as HIV and hepatitis C virus for decades.
DOI: 10.1002/cpt.2099
PubMed: 33113246
Affiliations:
- Italie, Royaume-Uni, Suisse, États-Unis
- Alabama, Angleterre, Californie, Colorado, Grand Londres, Lombardie, Maryland, Oxfordshire
- Londres, Milan, Oxford
- Université d'Oxford
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.</title><author><name sortKey="Boffito, Marta" sort="Boffito, Marta" uniqKey="Boffito M" first="Marta" last="Boffito">Marta Boffito</name><affiliation wicri:level="3"><nlm:affiliation>Chelsea & Westminster Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chelsea & Westminster Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Disease, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious Disease, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Back, David J" sort="Back, David J" uniqKey="Back D" first="David J" last="Back">David J. Back</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Flexner, Charles" sort="Flexner, Charles" uniqKey="Flexner C" first="Charles" last="Flexner">Charles Flexner</name><affiliation wicri:level="2"><nlm:affiliation>Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sjo, Peter" sort="Sjo, Peter" uniqKey="Sjo P" first="Peter" last="Sjö">Peter Sjö</name><affiliation wicri:level="1"><nlm:affiliation>Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Drugs for Neglected Diseases Initiative (DNDi), Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Blaschke, Terrence F" sort="Blaschke, Terrence F" uniqKey="Blaschke T" first="Terrence F" last="Blaschke">Terrence F. Blaschke</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Stanford University School of Medicine, Stanford, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Horby, Peter W" sort="Horby, Peter W" uniqKey="Horby P" first="Peter W" last="Horby">Peter W. Horby</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Cattaneo, Dario" sort="Cattaneo, Dario" uniqKey="Cattaneo D" first="Dario" last="Cattaneo">Dario Cattaneo</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Anderson, Peter" sort="Anderson, Peter" uniqKey="Anderson P" first="Peter" last="Anderson">Peter Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Owen, Andrew" sort="Owen, Andrew" uniqKey="Owen A" first="Andrew" last="Owen">Andrew Owen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33113246</idno><idno type="pmid">33113246</idno><idno type="doi">10.1002/cpt.2099</idno><idno type="wicri:Area/Main/Corpus">000216</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000216</idno><idno type="wicri:Area/Main/Curation">000216</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000216</idno><idno type="wicri:Area/Main/Exploration">000216</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.</title><author><name sortKey="Boffito, Marta" sort="Boffito, Marta" uniqKey="Boffito M" first="Marta" last="Boffito">Marta Boffito</name><affiliation wicri:level="3"><nlm:affiliation>Chelsea & Westminster Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chelsea & Westminster Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Disease, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious Disease, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Back, David J" sort="Back, David J" uniqKey="Back D" first="David J" last="Back">David J. Back</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Flexner, Charles" sort="Flexner, Charles" uniqKey="Flexner C" first="Charles" last="Flexner">Charles Flexner</name><affiliation wicri:level="2"><nlm:affiliation>Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sjo, Peter" sort="Sjo, Peter" uniqKey="Sjo P" first="Peter" last="Sjö">Peter Sjö</name><affiliation wicri:level="1"><nlm:affiliation>Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Drugs for Neglected Diseases Initiative (DNDi), Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Blaschke, Terrence F" sort="Blaschke, Terrence F" uniqKey="Blaschke T" first="Terrence F" last="Blaschke">Terrence F. Blaschke</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Stanford University School of Medicine, Stanford, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Horby, Peter W" sort="Horby, Peter W" uniqKey="Horby P" first="Peter W" last="Horby">Peter W. Horby</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Cattaneo, Dario" sort="Cattaneo, Dario" uniqKey="Cattaneo D" first="Dario" last="Cattaneo">Dario Cattaneo</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Anderson, Peter" sort="Anderson, Peter" uniqKey="Anderson P" first="Peter" last="Anderson">Peter Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Owen, Andrew" sort="Owen, Andrew" uniqKey="Owen A" first="Andrew" last="Owen">Andrew Owen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical pharmacology and therapeutics</title><idno type="eISSN">1532-6535</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The urgent global public health need presented by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has brought scientists from diverse backgrounds together in an unprecedented international effort to rapidly identify interventions. There is a pressing need to apply clinical pharmacology principles and this has already been recognized by several other groups. However, one area that warrants additional specific consideration relates to plasma and tissue protein binding that broadly influences pharmacokinetics and pharmacodynamics. The principles of free drug theory have been forged and applied across drug development but are not currently being routinely applied for SARS-CoV-2 antiviral drugs. Consideration of protein binding is of critical importance to candidate selection but requires correct interpretation, in a drug-specific manner, to avoid either underinterpretation or overinterpretation of its consequences. This paper represents a consensus from international researchers seeking to apply historical knowledge, which has underpinned highly successful antiviral drug development for other viruses, such as HIV and hepatitis C virus for decades.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33113246</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.2099</ELocationID><Abstract><AbstractText>The urgent global public health need presented by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has brought scientists from diverse backgrounds together in an unprecedented international effort to rapidly identify interventions. There is a pressing need to apply clinical pharmacology principles and this has already been recognized by several other groups. However, one area that warrants additional specific consideration relates to plasma and tissue protein binding that broadly influences pharmacokinetics and pharmacodynamics. The principles of free drug theory have been forged and applied across drug development but are not currently being routinely applied for SARS-CoV-2 antiviral drugs. Consideration of protein binding is of critical importance to candidate selection but requires correct interpretation, in a drug-specific manner, to avoid either underinterpretation or overinterpretation of its consequences. This paper represents a consensus from international researchers seeking to apply historical knowledge, which has underpinned highly successful antiviral drug development for other viruses, such as HIV and hepatitis C virus for decades.</AbstractText><CopyrightInformation>© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boffito</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chelsea & Westminster Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Back</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flexner</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sjö</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaschke</LastName><ForeName>Terrence F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horby</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattaneo</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Edward P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19056</GrantID><Agency>UKRI/NIHR</Agency><Country></Country></Grant><Grant><GrantID>215091/Z/18/Z</GrantID><Agency>Wellcome/DFiD</Agency><Country></Country></Grant><Grant><GrantID>AI122298</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI134091</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24AI118397</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EP/R024804/1</GrantID><Agency>EPSRC</Agency><Country></Country></Grant><Grant><GrantID>EP/S012265/1</GrantID><Agency>EPSRC</Agency><Country></Country></Grant><Grant><GrantID>761104</GrantID><Agency>European Commission</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33113246</ArticleId><ArticleId IdType="doi">10.1002/cpt.2099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arshad, U. et al. Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin. Pharmacol. Ther. 108, 775-790 (2020).</Citation></Reference><Reference><Citation>Acosta, E.P. et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob. Agents Chemother. 56, 5938-5945 (2012).</Citation></Reference><Reference><Citation>Boffito, M. et al. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19, 825-835 (2003).</Citation></Reference><Reference><Citation>Fischl, M.A. et al. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15, 28-34 (1997).</Citation></Reference><Reference><Citation>Boras, B. et al. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv. https://doi.org/10.1101/2020.09.12.293498. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Smolders, E.J., Te Brake, L.H. & Burger, D.M. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. Antivir. Ther. https://doi.org/10.3851/IMP365. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Smith, P.F., Dodds, M., Bentley, D., Yeo, K. & Rayner, C. Dosing will be a key success factor in repurposing antivirals for COVID-19. Br. J. Clin. Pharmacol. https://doi.org/10.1111/bcp.14314. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Baker, E.H., Gnjidic, D., Kirkpatrick, C.M.J., Pirmohamed, M., Wright, D.F.B. & Zecharia, A.Y. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. Br. J. Clin. Pharmacol. https://doi.org/10.1111/bcp.14416. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Smith, D.A., Di, L. & Kerns, E.H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov. 9, 929-939 (2010).</Citation></Reference><Reference><Citation>Trainor, G.L. The importance of plasma protein binding in drug discovery. Expert Opin. Drug Discov. 2, 51-64 (2007).</Citation></Reference><Reference><Citation>Bohnert, T. & Gan, L.S. Plasma protein binding: from discovery to development. J. Pharm. Sci. 102, 2953-2994 (2013).</Citation></Reference><Reference><Citation>Owen, A. & Khoo, S.H. Intracellular pharmacokinetics of antiretroviral agents. J. HIV Ther. 9, 97-101 (2004).</Citation></Reference><Reference><Citation>Whyte-Allman, S.K. & Bendayan, R. HIV-1 sanctuary sites-the role of membrane-associated drug transporters and drug metabolic enzymes. AAPS J. 22, 118 (2020).</Citation></Reference><Reference><Citation>Palmgren, J.J., Monkkonen, J., Korjamo, T., Hassinen, A. & Auriola, S. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur. J. Pharm. Biopharm. 64, 369-378 (2006).</Citation></Reference><Reference><Citation>Hickman, D. et al. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob. Agents Chemother. 48, 2911-2917 (2004).</Citation></Reference><Reference><Citation>Sham, H.L. et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42, 3218-3224 (1998).</Citation></Reference><Reference><Citation>Sheahan, T.P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).</Citation></Reference><Reference><Citation>Smith, S.A. & Waters, N.J. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm. Res. 36, 30 (2018).</Citation></Reference><Reference><Citation>Beigel, J.H. et al. Remdesivir for the treatment of covid-19 - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764. [e-pub ahead of print].</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics review of Kaletra oral solution (2001). Accessed August 20, 2020.</Citation> </Reference><Reference><Citation>Schoergenhofer, C., Jilma, B., Stimpfl, T., Karolyi, M., Zoufaly, A. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). Ann. Int. Med. 173, 670-672 (2020).</Citation></Reference><Reference><Citation>Gregoire, M. et al. Lopinavir pharmacokinetics in COVID-19 patients. J. Antimicrob. Chemother. 75, 2702-2704 (2020).</Citation></Reference><Reference><Citation>Baldelli, S., Corbellino, M., Clementi, E., Cattaneo, D. & Gervasoni, C. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J. Antimicrob. Chemother. 75, 2704-2706 (2020).</Citation></Reference><Reference><Citation>Marzolini, C. et al. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.01177-20. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Batteux, B. et al. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. Br. J. Clin. Pharmacol. https://doi.org/10.1111/bcp.14489. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Molla, A. et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250, 255-262 (1998).</Citation></Reference><Reference><Citation>Yamamoto, N., Matsuyama, S., Hoshino, T. & Yamamoto, N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. https://doi.org/10.1101/2020.04.06.026476. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Ko, M., Jeon, S., Ryu, W.S. & Kim, S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J. Med. Virol. https://doi.org/10.1002/jmv.26397. [e-pub ahead of print].</Citation></Reference><Reference><Citation>Cattaneo, D. et al. Does lopinavir really inhibit SARS-CoV-2? Pharmacol. Res. 158, 104898 (2020).</Citation></Reference><Reference><Citation>Humeniuk, R. et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19 healthy subjects. Clin. Trans. Sci. 13, 896-906 (2020).</Citation></Reference><Reference><Citation>Jorgensen, S.C.J., Kebriaei, R. & Dresser, L.D. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40, 659-671 (2020).</Citation></Reference><Reference><Citation>World Health Organization (WHO). Appendix 4. Summaries of evidence from selected experimental therapeutics, as of October 2018 (2018). Accessed August 20, 2020.</Citation> </Reference><Reference><Citation>Ter Heine, R., Mulder, J.W., van Gorp, E.C., Wagenaar, J.F., Beijnen, J.H. & Huitema, A.D. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br. J. Clin. Pharmacol. 69, 475-483 (2010).</Citation></Reference><Reference><Citation>Yan, V.C. & Muller, F.L. Advantages of the parent nucleoside GS-441524 over remdesivir for COVID-19 treatment. ACS Med. Chem. Lett. 11, 1361-1366 (2020).</Citation></Reference><Reference><Citation>Schmidt, S., Gonzalez, D. & Derendorf, H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 99, 1107-1122 (2010).</Citation></Reference><Reference><Citation>Benet, L.Z. & Hoener, B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).</Citation></Reference><Reference><Citation>Ceciliani, F. & Lecchi, C. The immune functions of alpha1 acid glycoprotein. Curr. Protein Pept. Sci. 20, 505-524 (2019).</Citation></Reference><Reference><Citation>Kimhofer, T. et al. Integrative modelling of quantitative plasma lipoprotein, metabolic and amino acid data reveals a multi-organ pathological signature of SARS-CoV-2 infection. J. Proteome Res. https://doi.org/10.1021/acs.jproteome.0c00519. [e-pub ahead of print].</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Alabama</li><li>Angleterre</li><li>Californie</li><li>Colorado</li><li>Grand Londres</li><li>Lombardie</li><li>Maryland</li><li>Oxfordshire</li></region><settlement><li>Londres</li><li>Milan</li><li>Oxford</li></settlement><orgName><li>Université d'Oxford</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Boffito, Marta" sort="Boffito, Marta" uniqKey="Boffito M" first="Marta" last="Boffito">Marta Boffito</name></region><name sortKey="Back, David J" sort="Back, David J" uniqKey="Back D" first="David J" last="Back">David J. Back</name><name sortKey="Boffito, Marta" sort="Boffito, Marta" uniqKey="Boffito M" first="Marta" last="Boffito">Marta Boffito</name><name sortKey="Horby, Peter W" sort="Horby, Peter W" uniqKey="Horby P" first="Peter W" last="Horby">Peter W. Horby</name><name sortKey="Owen, Andrew" sort="Owen, Andrew" uniqKey="Owen A" first="Andrew" last="Owen">Andrew Owen</name><name sortKey="Owen, Andrew" sort="Owen, Andrew" uniqKey="Owen A" first="Andrew" last="Owen">Andrew Owen</name></country><country name="États-Unis"><region name="Maryland"><name sortKey="Flexner, Charles" sort="Flexner, Charles" uniqKey="Flexner C" first="Charles" last="Flexner">Charles Flexner</name></region><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name><name sortKey="Anderson, Peter" sort="Anderson, Peter" uniqKey="Anderson P" first="Peter" last="Anderson">Peter Anderson</name><name sortKey="Blaschke, Terrence F" sort="Blaschke, Terrence F" uniqKey="Blaschke T" first="Terrence F" last="Blaschke">Terrence F. Blaschke</name></country><country name="Suisse"><noRegion><name sortKey="Sjo, Peter" sort="Sjo, Peter" uniqKey="Sjo P" first="Peter" last="Sjö">Peter Sjö</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Cattaneo, Dario" sort="Cattaneo, Dario" uniqKey="Cattaneo D" first="Dario" last="Cattaneo">Dario Cattaneo</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000191 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000191 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33113246
|texte= Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33113246" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |